MicroPort NeuroTech™ Bridge® Vertebral Drug-Eluting Stent Presents in Frontiers in Neurology with PESS Results
Shanghai, China, 20 December 2021 — MicroPort NeuroTech Limited (MicroPort NeuroTech™) has published the outcomes of the study ‘Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System (PESS),’ a pre-market clinical trial for the Bridge® Rapamycin Target Eluting Vertrbral Stent System (Bridge®, previously known as Firehorus).